Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BCBS-FEP replied again and here is my reply:
From your link,👇page that shows VASCEPA is an excluded medication & lists "covered options."
— Raf 🍊 (@ra_fun) January 12, 2023
Once again, I take VASCEPA for CVD risk reduction. It has a @US_FDA-apprpved label for CVD risk reduction.
But all "covered opinions" 💊 are NOT FDA-approved for CVD risk reduction! pic.twitter.com/3kwDxEkfAC
Dunno the legality of it but Denner should have gave Amarin an ultimatum:
By xx/xx/xxxx, either get the share price to $X or we want 7 seats on the BOD. Your bullet points mean nothing, we don't believe in participation trophies.
So what did you do with your prescription... you had your doctor send it to BlinkRx instead of your pharmacy?
What did BlinkRx do after?
"Insanity is doing the same thing over and over and expecting different results," Albert Einstein.
New poll, Denner or Amarin? Vote.
As a shareholder of $AMRN, which team would you choose? #Vascepa
— Raf 🍊 (@ra_fun) January 11, 2023
Call the number that's on the back of your card and transfer to a pharmacist.
I spoke to them last week and lost several IQ points. The moron could not comprehend that:
1) gV does not have a CV label
2) Lovaza reducing TG isn't the same as V reducing CV risk
He seriously told me that Lovaza reduced TG, which ultimately reduces CV risk.
BCBS-FEP replied and I replied back.
Please DM us your name, date of birth, member ID number, and preferred call back number.
— BCBS - FEP (@fepblue) January 11, 2023
I renew my request to anyone here who is in communication with IR to ask them if Amarin had tested Generics for biological differences to Vascepa.
Dr Bhatt isn't aware of any such studies and I can't imagine Amarin doing anything of that magnitude without running it by Bhatt.
I had assumed those would be worthwhile studies to do and be funded, but that did not happen. So, the only data (not anecdote) that exist are the data the FDA would have required and whatever internal data the company would have likely generated themselves (again, me assuming).
— Dr. Deepak L. Bhatt (@DLBHATTMD) November 6, 2022
Today is exactly 1 year since the MITIGATE trial website has been updated.
https://clinicaltrials.gov/ct2/show/NCT04505098
Looks like Denner has been watching 20 Republicans in the House of Representatives operate last week:
Burn it all down (figuratively speakers) or change the damn rules.
I have a feeling this will receive many likes.
Greetings from #SF! Reminder: Our President and CEO, Karim Mikhail will be presenting today at #JPM23. Watch the webcast live at 8:15 p.m. ET/ 5:15 p.m. PST: https://t.co/pdPtScjHiY pic.twitter.com/da5WcQVt8k
— Amarin (@Amarincorp) January 10, 2023
New website https://amarincorp.com/
My philosophy professor would be proud of me
Morale of the story: take Vascepa 😁
— Raf 🍊 (@ra_fun) January 7, 2023
Scripts for week ending December 30, 2022 - Christmas
Drug Industry TRx: -6.7% w/w; +6.4% y/y
Vascepa
TRx 58,502; -7.0% (-4,434) w/w; -18.8% y/y
NRx 24,493; -15.6% (-1,131) w/w; -17.5% y/y
Ref 34,009; +0.2% (+84) w/w; -19.6% y/y
Fake Vascepa
TRx 37,910; -10.5% (-4,428) w/w; As % of total V: 39.3%
NRx 16,092; -18.4% (-3,622) w/w; As % of total V: 39.7%
Ref 21,818; -3.6% (-806) w/w; As % of total V: 39.1%
Fake Vascepa by Manufacturer
Hikma - TRx 13,672; -1,072 w/w; Generic share 36.1%; Total V share 14.2%
Reddy - TRx 16,608; -2,896 w/w; Generic share 43.8%; Total V share 17.2%
Apotex - TRx 7,454; -378 w/w; Generic share 19.7%; Total V share 7.7%
Teva - TRx 177; -82 w/w; Generic share 0.5%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 96,412; -8.4% (-8,862) w/w; +1.8% y/y
NRx 40,585; -16.7% (-8,141) w/w; -2.9% y/y
Ref 55,827; -1.3% (-722) w/w; +5.6% y/y
Lovaza (Fake & Brand)
TRx 57,779; -9.5% (-6,044) w/w; +0.3% y/y
NRx 25,576; -16.7% (-5,129) w/w; -4.3% y/y
Ref 32,203; -2.8% (-915) w/w; +4.2% y/y
Isn't it silly that despite all the current technology, we don't have a device that can tell us instantly what we have?
I don't mean rapid covid tests. I mean a device that can tell if you have flu, covid, cold, etc? It's silly having to call a doctor every time your child is sick, just to come on and do a stupid test for flu.
Both my parents (in their 70s) just had COVID. They're vaxxed (March 2021) and not boosted.
Dad: days 1-2: 101 fever, mild cough & oxygen level down to 90, increased Vascepa from 4g to 6g for first 4 days.
Mom: nausea and tiredness days 1-3, no other symptoms. Stayed on 4g of Vascepa.
This happened last week. No additional symptoms.
Pleased donate. Sue has helped a ton.
https://www.gofundme.com/f/celebrating-the-life-of-sue-morgan
Great work. Please inform (email & Twitter) BCBS of this and of your intent to follow through with the aforementioned agencies.
I just spoke with a BCBS pharmacist and OMG! He told me that Vascepa and Lovaza are "essentially the same thing, they both reduce TG". He also could not grasp that Vascepa and gV have different labels, after I told him 5 times (not exaggerating).
Dunno how she does it but 13k views and 300 likes in 4 hours is amazing.
Starting tonight! Please let this work! pic.twitter.com/sb9XvNQ4wr
— LongCovidPharmD (@organichemusic) January 4, 2023
I urge everyone (Louie, Rose, Z, others) who has BCBS-FEP to call them and speak to their pharmacist about this.
Pick their brain.
• Why do they suggest non-CVD drugs to reduce CVD risk?
• Do they think Vascepa & Lovaza are interchangeable?
• What do they mean by "try and fail"?
Please report the conversation back here.
https://stocktwits.com/rafunrafun/message/504224285
Please like and retweet, as I will keep pounding them.
@fepblue - I've been taking Vascepa to reduce my CVD risk but you no longer cover it in 2023 - WHY?! pic.twitter.com/gGq7FTs58u
— Raf 🍊 (@ra_fun) January 1, 2023
If a BP can have V, which cures migraines and cold sores on top of CVD and tie up the API for Generics and tell the world that this is the greatest thing since sliced bread = 500k Rx weekly.
I brought this up before...
After starting to take Vascepa, cold sores and migraines have disappeared for me. It's been 7 years and I haven't gotten any, despite getting both, often, prior to Vascepa.
Do others have similar experiences?
It's gross that this isn't being studied more.
Scripts for week ending December 23, 2022
Drug Industry TRx: -3.3% w/w; +10.2% y/y
Vascepa
TRx 62,936; -3.9% (-2,552) w/w; -15.3% y/y
NRx 29,011; -3.8% (-1,131) w/w; -14.0% y/y
Ref 33,925; -4.0% (-1,422) w/w; -16.4% y/y
Fake Vascepa
TRx 42,338; -4.1% (-1,832) w/w; As % of total V: 40.2%
NRx 19,715; -4.6% (-956) w/w; As % of total V: 40.5%
Ref 22,624; -3.7% (-875) w/w; As % of total V: 40.0%
Fake Vascepa by Manufacturer
Hikma - TRx 14,744; -661 w/w; Generic share 34.8%; Total V share 14.0%
Reddy - TRx 19,504; -993 w/w; Generic share 46.1%; Total V share 18.5%
Apotex - TRx 7,832; -155 w/w; Generic share 18.5%; Total V share 7.4%
Teva - TRx 259; -12 w/w; Generic share 0.6%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 105,275; -4.0% (-4,384) w/w; +6.9% y/y
NRx 48,726; -4.1% (-2,087) w/w; +1.3% y/y
Ref 56,549; -3.9% (-2,297) w/w; +12.3% y/y
Lovaza (Fake & Brand)
TRx 63,823; -4.2% (-2,809) w/w; +6.4% y/y
NRx 30,705; -6.8% (-2,232) w/w; +2.4% y/y
Ref 33,118; -1.7% (-577) w/w; +10.5% y/y
A message for Nissen... like & retweet
👋 Cleveland Clinic
— Raf 🍊 (@ra_fun) December 27, 2022
Could one of you astute folks please pass this link to Steven Nissen, as he's been having comprehension problems with VASCEPA?@ClevelandClinic @ClevClinicHeart @CCFcards @CleClinicNews@DLBHATTMD @VietHeartPA @BudoffMd @mmillermd1https://t.co/QyTstbxWYb
I have way more questions than answers.
This was posted almost 16 months ago.
Congrats to the MITIGATE team for finishing recruitment in a first-in-class virtual, EHR-based pragmatic trial of IPE for viral URI prevention in high-risk ASCVD with automated data collection and no F2F encounters! @asgmd1 @ThidaChanTan @rvparikh @MDSolomonMD @KPDOR @DLBHATTMD pic.twitter.com/hAzdYK5AVy
— Andrew P. Ambrosy, MD (@KPHeartDoc) September 1, 2021
If you are dealing with an insurance company about Vascepa, please be cognizant that there is a possibility that your interaction may be an example of infringement.
Document it - make sure you tell them in writing that you take Vascepa for CVD risk reduction. If after that, they still tell you to get gV or Lovaza, that may be costly for them. Amarin can't ask you to do this, but I can and plan on doing the same, if an opportunity arises.
That's an easy one. You tried gV and it gave you heartburn and fish burps.
But if BCBS want to play games, let them put in writing that they want you to try Lovaza or gV, AFTER you inform them that you need it for CVD risk reduction - Marjac may be salivating.
When getting quotes, I think a 90-day supply may be substantially cheaper than a 30-day supply. Be sure to get both quotes, in 2023.
All may not be lost with BCBS-FEP.
Although Vascepa will not be in their 2023 formulary, they have a "Formulary Exception" process - your doctor fills out a form and submts it to BCBS.
Yes, the majority will not know about this but you guys do know.
Starting 2023, have your doctor fill out the Formulary Exception Form. If approved,
you will be charged for it as a tier 3 drug, as it was in 2022. Hopefully, it will still remain $9 for 90 days - fingers crossed.
https://www.fepblue.org/claim-forms
Scripts for week ending December 16, 2022
Drug Industry TRx: -0.3% w/w; +6.4% y/y
Vascepa
TRx 65,489; +0.5% (+350) w/w; -19.3% y/y
NRx 30,142; +0.9% (+279) w/w; -19.7% y/y
Ref 35,347; +0.2% (+71) w/w; -18.9% y/y
Fake Vascepa
TRx 44,170; +1.5% (+633) w/w; As % of total V: 40.3%
NRx 20,671; +1.2% (+241) w/w; As % of total V: 40.7%
Ref 23,499; +1.7% (+391) w/w; As % of total V: 39.9%
Fake Vascepa by Manufacturer
Hikma - TRx 15,405; +219 w/w; Generic share 34.9%; Total V share 14.0%
Reddy - TRx 20,497; +535 w/w; Generic share 46.4%; Total V share 18.7%
Apotex - TRx 7,987; -153 w/w; Generic share 18.1%; Total V share 7.3%
Teva - TRx 271; +32 w/w; Generic share 0.6%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 109,659; +0.9% (+983) w/w; +2.8% y/y
NRx 50,813; +1.0% (+520) w/w; -2.2% y/y
Ref 58,846; +0.8% (+463) w/w; +7.5% y/y
Lovaza (Fake & Brand)
TRx 66,632; +0.9% (+623) w/w; +2.8% y/y
NRx 32,937; +3.0% (+967) w/w; +0.0% y/y
Ref 33,695; -1.0% (-344) w/w; +5.6% y/y
I've never seen any Vascepa related tweet get anywhere the amount of likes and retweets as this one got ... and I'm just 1 day.
I didn't do a deep dive yet, but this is interesting.
20,500 followers.
600 likes on this tweet.
See full thread. Wow!
HIGH-DOSE EPA for LongCovid or ME/CFS?
— LongCovidPharmD (@organichemusic) December 17, 2022
Recently I spoke w/ an MD who has treated ~40 #pwLC with an Rx omega-3 fatty acid similar to EPA known as icosapent ethyl (IPE, brand name Vascepa) w/ promising results. Turns out, it may help #pwME too.
Details👇https://t.co/qRyHQjXcpj
Still under review, as of this morning.
Scripts for week ending December 9, 2022
Drug Industry TRx: +0.4% w/w; +6.8% y/y
Vascepa
TRx 65,138; -0.2% (-122) w/w; -21.6% y/y
NRx 29,863; +0.8% (+227) w/w; -20.8% y/y
Ref 35,276; -1.0% (-348) w/w; -22.3% y/y
Fake Vascepa
TRx 43,537; +1.9% (+797) w/w; As % of total V: 40.1%
NRx 20,430; +4.6% (+893) w/w; As % of total V: 40.6%
Ref 23,108; -0.4% (-96) w/w; As % of total V: 39.6%
Fake Vascepa by Manufacturer
Hikma - TRx 15,186; +461 w/w; Generic share 34.9%; Total V share 14.0%
Reddy - TRx 19,962; +262 w/w; Generic share 45.9%; Total V share 18.4%
Apotex - TRx 8,150; +83 w/w; Generic share 18.7%; Total V share 7.5%
Teva - TRx 239; -9 w/w; Generic share 0.5%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 108,676; +0.6% (+675) w/w; +1.6% y/y
NRx 50,292; +2.3% (+1,120) w/w; -1.6% y/y
Ref 58,383; -0.8% (-445) w/w; +4.5% y/y
Lovaza (Fake & Brand)
TRx 66,009; +1.1% (+711) w/w; +0.4% y/y
NRx 31,970; +3.2% (+993) w/w; -2.3% y/y
Ref 34,039; -0.8% (-282) w/w; +3.1% y/y
Shame tweet.
👋 @fepblue
— Raf 🍊 (@ra_fun) December 16, 2022
The people have spoken. See results, 77-0 🔥
Maybe you should work something out with @Amarincorp to reinstate VASCEPA in your 2023 formulary. https://t.co/OBESKPMdkF pic.twitter.com/fiJwJC2VHk